Kennedy T J, Sonneland A M, Marlett M M, Troup R H
J Urol. 1992 Mar;147(3 Pt 2):891-3. doi: 10.1016/s0022-5347(17)37414-1.
A total of 7 patients with clinical stage C prostate cancer determined by digital rectal examination, transrectal ultrasonography, radionuclide bone scanning and serum prostatic acid phosphatase determination was treated with luteinizing hormone-releasing hormone analogues for 2 to 5 months in an attempt to downstage the disease. Although substantial decreases in prostate specific antigen level and prostatic volume occurred, only 2 patients experienced pathological downstaging of disease. We conclude that luteinizing hormone-releasing hormone therapy for downstaging of clinical stage C prostatic cancer is of limited value.
通过直肠指检、经直肠超声检查、放射性核素骨扫描及血清前列腺酸性磷酸酶测定确诊为临床C期前列腺癌的7例患者，接受了促黄体生成素释放激素类似物治疗2至5个月，以期使疾病降期。尽管前列腺特异性抗原水平和前列腺体积大幅下降，但只有2例患者出现疾病的病理降期。我们得出结论，促黄体生成素释放激素疗法用于临床C期前列腺癌降期的价值有限。
